The association of tumor-to-background ratios and SUVmax deviations related to point spread function and time-of-flight F18-FDG-PET/CT reconstruction in colorectal liver metastases

Bonanni L, De’liguori Carino N, Deshpande R, Ammori BJ, Sherlock DJ, Valle JW, et al.: A comparison of diagnostic imaging modalities for colorectal liver metastases. Eur J Surg Oncol 2014,40(5):545–50. 10.1016/j.ejso.2013.12.023

Chua SC, Groves AM, Kayani I, Menezes L, Gacinovic S, Du Y, et al.: The impact of 18 F-FDG PET/CT in patients with liver metastases. Eur J Nucl Med Mol Imaging 2007,34(12):1906–14. 10.1007/s00259-007-0518-y

Kong G, Jackson C, Koh DM, Lewington V, Sharma B, Brown G, et al.: The use of 18 F-FDG PET/CT in colorectal liver metastases - comparison with CT and liver MRI. Eur J Nucl Med Mol Imaging 2008,35(7):1323–9. 10.1007/s00259-008-0743-z

Selzner M, Hany TF, Wildbrett P, McCormack L, Kadry Z, Clavien PA: Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg 2004,240(6):1027–34. 10.1097/01.sla.0000146145.69835.c5

Hendlisz A, Golfinopoulos V, Garcia C, Covas A, Emonts P, Ameye L, et al.: Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy. Ann Oncol 2012,23(7):1687–93. 10.1093/annonc/mdr554

Parlak C, Topkan E, Sonmez S, Onal C, Reyhan M: CT- versus coregistered FDG-PET/CT-based radiation therapy plans for conformal radiotherapy in colorectal liver metastases: a dosimetric comparison. Jpn J Radiol 2012,30(8):628–34. 10.1007/s11604-012-0101-8

Riou O, Serrano B, Azria D, Paulmier B, Villeneuve R, Fenoglietto P, et al.: Integrating respiratory-gated PET-based target volume delineation in liver SBRT planning, a pilot study. Radiat Oncol 2014, 9: 127. 10.1186/1748-717X-9-127

Ramos CD, Erdi YE, Gonen M, Riedel E, Yeung HW, Macapinlac HA, et al.: FDG-PET standardized uptake values in normal anatomical structures using iterative reconstruction segmented attenuation correction and filtered back-projection. Eur J Nucl Med 2001,28(2):155–64. 10.1007/s002590000421

Cheebsumon P, Yaqub M, van Velden FH, Hoekstra OS, Lammertsma AA, Boellaard R: Impact of [18 F]FDG PET imaging parameters on automatic tumour delineation: need for improved tumour delineation methodology. Eur J Nucl Med Mol Imaging 2011,38(12):2136–44. 10.1007/s00259-011-1899-5

Prieto E, Domínguez-Prado I, García-Velloso MJ, Peñuelas I, Richter JÁ, Martí-Climent JM: Impact of time-of-flight and point-spread-function in SUV quantification for oncological PET. Clin Nucl Med 2013,38(2):103–9. 10.1097/RLU.0b013e318279b9df

Knäusl B, Hirtl A, Dobrozemsky G, Bergmann H, Kletter K, Dudczak R, et al.: PET based volume segmentation with emphasis on the iterative TrueX algorithm. Z Med Phys 2012,22(1):29–39. 10.1016/j.zemedi.2010.12.003

Knäusl B, Rausch IF, Bergmann H, Dudczak R, Hirtl A, Georg D: Influence of PET reconstruction parameters on the TrueX algorithm. A combined phantom and patient study Nuklearmedizin 2013,52(1):28–35.

Rogasch JMM, Hofheinz F, Lougovski A, Furth C, Ruf J, Großer OS, et al.: The influence of different signal-to-background ratios on spatial resolution and F18-FDG-PET quantification using point spread function and time-of-flight reconstruction. EJNMMI Physics 2014, 1: 12. 10.1186/2197-7364-1-12

Boellaard R, O’Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al.: FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 2010,37(1):181–200. 10.1007/s00259-009-1297-4

Panin VY, Kehren F, Michel C, Casey M: Fully 3-D PET reconstruction with system matrix derived from point source measurements. IEEE Trans Med Imaging 2006,25(7):907–21. 10.1109/TMI.2006.876171

Akamatsu G, Mitsumoto K, Taniguchi T, Tsutsui Y, Baba S, Sasaki M: Influences of point-spread function and time-of-flight reconstructions on standardized uptake value of lymph node metastases in FDG-PET. Eur J Radiol 2014,83(1):226–30. 10.1016/j.ejrad.2013.09.030

Rahmim A, Qi J, Sossi V: Resolution modeling in PET imaging: theory, practice, benefits, and pitfalls. Med Phys 2013,40(6):064301. 10.1118/1.4800806

Schaefferkoetter J, Casey M, Townsend D, El Fakhri G: Clinical impact of time-of-flight and point response modeling in PET reconstructions: a lesion detection study. Phys Med Biol 2013,58(5):1465–78. 10.1088/0031-9155/58/5/1465

Taniguchi T, Akamatsu G, Kasahara Y, Mitsumoto K, Baba S, Tsutsui Y, et al.: Improvement in PET/CT image quality in overweight patients with PSF and TOF. Ann Nucl Med 2015,29(1):71–7. 10.1007/s12149-014-0912-z

El Fakhri G, Surti S, Trott CM, Scheuermann J, Karp JS: Improvement in lesion detection with whole-body oncologic time-of-flight PET. J Nucl Med 2011,52(3):347–53. 10.2967/jnumed.110.080382

Vesselle H, Schmidt RA, Pugsley JM, Li M, Kohlmyer SG, Vallires E, et al.: Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res 2000,6(10):3837–44.

Hallett WA, Marsden PK, Cronin BF, O’Doherty MJ: Effect of corrections for blood glucose and body size on [18 F]FDG PET standardised uptake values in lung cancer. Eur J Nucl Med 2001,28(7):919–22. 10.1007/s002590100561

Murray I, Kalemis A, Glennon J, Hasan S, Quraishi S, Beyer T, et al.: Time-of-flight PET/CT using low-activity protocols: potential implications for cancer therapy monitoring. Eur J Nucl Med Mol Imaging 2010,37(9):1643–53. 10.1007/s00259-010-1466-5

Surti S, Kuhn A, Werner ME, Perkins AE, Kolthammer J, Karp JS: Performance of Philips Gemini TF PET/CT scanner with special consideration for its time-of-flight imaging capabilities. J Nucl Med 2007,48(3):471–80.

Bundschuh RA, Andratschke N, Dinges J, Duma MN, Astner ST, Brügel M, et al.: Respiratory gated [18 F]FDG PET/CT for target volume delineation in stereotactic radiation treatment of liver metastases. Strahlenther Onkol 2012,188(7):592–8. 10.1007/s00066-012-0094-3

Nestle U, Kremp S, Schaefer-Schuler A, Sebastian-Welsch C, Hellwig D, Rübe C, et al.: Comparison of different methods for delineation of 18 F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-small cell lung cancer. J Nucl Med 2005,46(8):1342–8.